Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B.
Natasha Pillay-SmileyJames LeachAdam LaneTrent HummelJason FangusaroPeter M K de BlankPublished in: Cancers (2023)
Treatment with selumetinib did not affect the overall FASI size in children with NF1 treated for progressive low-grade glioma.